uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Investigation of RRM2 as a potential therapeutic target against glioblastoma
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Biology Education Centre. (Institute of Immunology, Genetics and Pathology)
2017 (English)Independent thesis Advanced level (degree of Master (Two Years)), 30 credits / 45 HE creditsStudent thesis
Abstract [en]

Title: Investigation of RRM2 as a potential therapeutic target against glioblastoma

Supervisors: Dr. Sven Nelander and Mr. Sathishkumar Baskaran.

Department: Department of Immunology, genetics and pathology

(IGP), Uppsala University

 

Glioblastoma (GBM) is the most malignant form of glioma and associated with high proliferation rate, necrosis and highly invasive nature. Current treatment includes tumor resection followed by combination of radiotherapy and chemotherapy with temozolomide (TMZ). Despite of combination therapy, GBM exhibits dismal prognosis and mean survival rate of patients is only 3.3 % at 2 years and 1.2 % at 3 years. Therefore, there is an increasing demand of identifying new therapeutic targets against GBM. In this project, we studied the function of RRM2 gene as a potential therapeutic target in two patients derived GBM cell lines (GC). By knocking down RRM2 using short interfering RNAs, the viability of cells and proliferation was significantly reduced in both the GC. The cause of cell death was due to induction of apoptosis by the treatment in GC. Treatment of COH29, an inhibitor of RNR, induced cell death at therapeutically relevant dose in GC. Our results indicate that RRM2 has a significant role in GBM cell growth/proliferation. More evaluation must be performed in both in-vitro and in-vivo to pursue RRM2 as a molecular therapeutic target against GBM.

Place, publisher, year, edition, pages
2017. , p. 34
Keywords [en]
cancer, glioblastoma, RRM2
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-337136OAI: oai:DiVA.org:uu-337136DiVA, id: diva2:1168455
Educational program
Master Programme in Biology
Supervisors
Examiners
Available from: 2020-02-19 Created: 2017-12-20 Last updated: 2020-02-19Bibliographically approved

Open Access in DiVA

The full text will be freely available from 2022-08-21 15:04
Available from 2022-08-21 15:04

By organisation
Biology Education Centre
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 5 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf